Abstract
We studied 21 bone marrow specimens from 21 patients with systemic lupus erythematosus (SLE) and peripheral cytopenias: anaemia (Hb<10 g/dl), and/or leucopenia (white blood cell count <4×109/l), and/or thrombocytopenia (platelets <150×109/l). None of the patients had used immunosuppressive drugs in the 2 months before the study, and 11 (52.4%) had never used these drugs. The global and specific series cellularity, degree of fibrosis and necrosis were evaluated by bone marrow trephine; morphological abnormalities and iron stores were evaluated by cytological smears. The most important abnormalities viewed in bone marrow biopsies were: global hypocellularity (47.6%), increased reticulin proliferation (76.2%) with myelofibrosis in one patient, and necrosis (19.0%). The marrow aspirates were difficult to obtain in four patients, who showed an increased reticulin proliferation on histological analysis. Plasmocytosis was present in 26.7% of cases and in one there was a serum monoclonal component (IgG kappa). Iron stores were normal or increased in 26.7% of specimens and decreased or absent in 73.3%. The most frequent peripheral abnormality was leucopenia in 90.4% (19/21) and granulocytic hypoplasia was observed in 47.3% (9/19) of these patients. We conclude that the bone marrow may be a target organ in SLE with cytopenias.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Budman, DR, Steinberg AD. Hematologic aspects of systemic lupus erythematosus: current concepts. Ann Intern Med 1977;86:220–9.
Richert-Boe KE. Hematologic complications of rheumatic disease. Hematol Oncol Clin North Am 1987;1:301–20.
Quismorio FP. Hemic and lymphatic abnormalities in SLE. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. Philadelphia: Lea & Febiger, 1993:418–30.
Nichols CR, Akard LP. Hematologic problems in patients with cancer and chronic inflammatory disorders. In: Hoffman R, Benz Jr EJ, Shattil SJ, Furie B, Cohen HJ, editors. Hematologic basic principles and practice. Edinburgh: Churchill Livingstone, 1984;1733–46.
Michael SR, Vural IL, Bassen FA, Schaefer L. The hematologic aspects of disseminated (systemic) lupus erythematosus. Blood 1951;6:1059–72.
Burkhardt R. The bone marrow in systemic lupus erythematosus. Semin Hematol 1965;2:29–46.
Brooks BJ Jr, Broxmeyer HE, Bryan CF, Leech SH. Serum inhibitor in systemic lupus erythematosus associated with aplasia anemia. Arch Intern Med 1984;144:1474–7.
Bailey FA, Lilly M, Bertoli LF, Ball GV. An antibody that inhibits in vitro bone marrow proliferation in a patient with systemic lupus erythematosus and aplastic anemia. Arthritis Rheum 1989;32:901–5.
Fitchen JJ, Cline MJ, Saxon A, Golde DW. Serum inhibitors of hematopoiesis in a patient with aplastic anemia and systemic lupus erythematosus: recovery after exchange plasmapheresis. Am J Med 1979;66:537–42.
Stricher RB, Shuman MA. Aplastic anemia complicating systemic lupus erythematosus: response to androgen in two patients. Am J Hematol 1984;17:193–201.
Roffe C, Cahill MR, Samanta A, Bricknell S, Durrant STS. Aplastic anaemia in systemic lupus erythematosus: a cellular immune mechanism? Br J Rhematol 1991;30:301–4.
Abdou NI, Lindsley HB, Pollock A, Stechschulte DJ, Wood G. Plasmapheresis in active systemic lupus erythematosus: effects on clinical, serum and cellular abnormalities. Clin Immunol Immunopathol 1981;19:44–54.
Walport MJ, Hubbard WN, Hughes GRV. Reversal of aplastic anaemia secondary to systemic lupus erythematosus by high-dose intravenous cyclophosphamide. Br Med J 1982;285:769–70.
Daly HM, Scott GL. Myelofibrosis as cause of pancytopenia in systemic lupus erythematosus. J Clin Pathol 1983;36:1219–22.
Kaelin WG, Spivak JK. Systemic lupus erythematosus and myelofibrosis. Am J Med 1986;81:935–8.
Borba EF, Pereira RMR, Velloso EDRP, et al. Neutropenia associated with myelofibrosis in systemic lupus erythematosus. Acta Haematol 1993;89:82–5.
Matsouka CH, Liouris J, Andrianakos A, Papademetriou C, Karvountzis G. Systemic lupus erythematosus and myelofibrosis. Clin Rheumatol 1989;8:402–7.
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for classification of systemic lupus erythematosus. Arthritis Rheum 1982;22:1382–5.
Urowitz MB, Gladman DD, Tozman ECS, Goldsmith CH. The lupus activity criteria count (LACC). J Rheumatol 1984;11:783–7.
Rosenthal NS, Farhi DC. Bone marrow findings in connective tissue disease. Am J Clin Pathol 1989;92:650–4.
Cappio FG, Gavosto F. Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis. Br J Hematol 1981;49:17–21.
Lang JM, Heid E. Auto-immunity in primary myelofibrosis. Biomedicine 1976;25:39.
Bernhardt B, Valleta M. Lupus anticoagulant in myelofibrosis. Am J Med Sci 1976;272:229–31.
Gordon BR, Day NK. Immunologic abnormalities in myelofibrosis with activation of the complement system. Blood 1981;58:904–10.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pereira, R.M.R., Velloso, E.R.P., Menezes, Y. et al. Bone marrow findings in systemic lupus erythematosus patients with peripheral cytopenias. Clin Rheumatol 17, 219–222 (1998). https://doi.org/10.1007/BF01451051
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01451051